Advertisement
Table 3 Frequency, detailed combination patterns, progression-free survival, overall survival and response to first-generation TKIs of compound EGFR mutations
| Subgroup of compound EGFR mutations | Frequency (n, %) | Mutated exons | Response (rate, %) | PFS (range, months) | OS (range, months) |
|---|---|---|---|---|---|
| Double common | 5 (4.7) | 25.0% | 10.1 ± 2.4 | 24.2 ± 8.2 | |
| 19Del + L858R | 5 | 19 and 21 | 3PR, 1SD, 1PD | 4.9–12 | 13.1–25.6 |
| Common + rare | 11 (10.4) | 45.5% | 10.5 ± 3.9 | Not reached | |
| 19Del + L861Q | 2 | 19 and 21 | 1PR, 1SD | 11.9–14.4 | 26.5–41.2 |
| L858R + S720P | 1 | 21 and 18 | PD | 2.1 | 2.1 |
| L858R + K757R | 1 | 21 and 19 | PR | 9.0 | 8.7 |
| L858R + I744 M | 1 | 21 and 19 | PR | 17.6 | 41.2 |
| L858R + S768I | 3 | 21 and 20 | 1PR, 1PD, 1SD | 1.8–6.2 | 4.0–12.5 |
| L858R + R776H | 1 | 21 and 20 | PR | 10.5 | 12.6 |
| L858R + L858Q | 1 | 21 and 21 | NE | 1 | 3 |
| L858R + L833V | 1 | 21 and 21 | SD | 5.0 | 15.9 |
| Common + T790M | 69 (65.1) | 56.5% | 10.3 ± 0.6 | Not reached | |
| 19Del + T790M | 43 | 19 and 20 | 27PR, 12SD, 2 PD, 2NE | 0.6–40.7 | 0.2–88.5 |
| L858R + T790M | 26 | 21 and 20 | 12PR, 10SD, 3PD, 1NE | 0.9–24.1 | 1.2–56.6 |
| Rare + rare | 13 (12.3) | 38.5% | 6.5 ± 1.3 | Not reached | |
| G719C + S768I | 1 | 18 and 20 | PR | 6.5 | 13.2 |
| G719S + S768I | 2 | 18 and 20 | 1PR, 1SD | 1–8.0 | 2.0–8.4 |
| G719S + L858Q | 1 | 18 and 21 | SD | 6.4 | 29.3 |
| G719X + S768I | 3 | 18 and 20 | 2PR, 1SD | 2.0–18 | 2.0–44.0 |
| G719X + L858Q | 3 | 18 and 21 | 1SD, 1PD, 1NE | 0.3–27.3 | 2.3–29.2 |
| G719S + E709A | 1 | 18 and 18 | PR | 4.1 | 4.1 |
| G719S + L858Q | 1 | 18 and 21 | SD | 6.4 | 29.3 |
| S768I + V774M | 1 | 20 and 20 | PD | 2.0 | 13.8 |
| Rare + T790M | 8 (7.5%) | 37.5% | 5.4 ± 2.5 | 23.8 ± 1.5 | |
| G719X + T790M | 1 | 18 and 20 | PR | 11.1 | 55.6 |
| D761Y + T790M | 2 | 19 and 20 | 2PD | 1.1–5.5 | 1.1–8.5 |
| L858Q + T790M | 5 | 21 and 20 | 2PR, 1SD, 2PD | 1.4–20.6 | 18–88.3 |
